RxDoctor Payments Data

Shafiqul Alam, MD

Internal Medicine · Rochester Hills, MINPI 1649258021

Payments from drug & device makers

$6,002in general payments, 2019–2025

Across 360 payments — averaging $16.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$595
  • Astellas Pharma US Inc$579
  • AbbVie$533
  • Lilly USA, LLC$441
  • GSK$405
  • Pfizer$367
  • plus $3K from 44 others

What the payments were for

  • Food & beverage$5,90298%
  • Education$1002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,002 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$81,093
Medicare patients
175
Services billed
1,122

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin90$119,148
EliquisApixaban64$84,522
MounjaroTirzepatide63$79,154
OzempicSemaglutide42$77,510
Trelegy ElliptaFluticasone/Umeclidin/Vilanter53$49,369
JanuviaSitagliptin Phosphate36$33,760
MyrbetriqMirabegron36$31,202
EntrestoSacubitril/Valsartan15$17,794
Desvenlafaxine Succinate ErDesvenlafaxine Succinate182$12,628
Mirabegron ErMirabegron12$9,878
Lantus SolostarInsulin Glargine,hum.Rec.Anlog46$5,635
Atorvastatin Calcium288$3,147
Losartan Potassium193$2,830
Rosuvastatin Calcium175$2,815
Levothyroxine Sodium227$2,574

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$235$119,14890 claims
PfizerEliquis$367$84,52264 claims
Lilly USA, LLCMounjaro$441$79,15463 claims
Novo NordiskOzempic$595$77,51042 claims
GSKTrelegy Ellipta$405$49,36953 claims
MerckJanuvia$184$33,76036 claims
Astellas Pharma US IncMyrbetriq$579$31,20236 claims
NovartisEntresto$194$17,79415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Rochester Hills

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →